Researchers from The University of Texas Medical Branch at Galveston have developed the first vaccine for chikungunya fever made from an insect-specific virus that doesn’t have any effect on people, making the vaccine safe and effective. The newly developed vaccine quickly produces a strong immune defense and completely protects mice and nonhuman primates from disease when exposed to the chikungunya virus.
The findings are detailed in Nature Medicine.
“This vaccine offers efficient, safe and affordable protection against chikungunya and builds the foundation for using viruses that only infect insects to develop vaccines against other insect-borne diseases,” said UTMB professor Scott Weaver, senior author of this paper.
Chikungunya is a mosquito-borne virus that causes a disease characterized by fever and severe joint pain, often in hands and feet, and may include headache, muscle pain, joint swelling, or rash. Some patients will feel better within a week but many develop longer-term joint pain that can last up to years. Death is rare but can occur.
Traditionally, vaccine development involves tradeoffs between how quickly the vaccine works and safety. Live-attenuated vaccines that are made from weakened versions of a live pathogen typically offer rapid and durable immunity but reduced safety. On the other hand, the inability of inactivated vaccines to replicate enhances safety at the expense of effectiveness, often requiring several doses and boosters to work properly. There may be a risk of disease with both of these vaccine types, either from incomplete inactivation of the virus or from incomplete or unstable weakening of the live virus that is only recognized when rare vulnerable individuals develop disease.
To overcome these tradeoffs, the researchers used the Eilat virus as a vaccine platform since it only infects insects and has no impact on people. The UTMB researchers used an Eilat virus clone to design a hybrid virus-based vaccine containing chikungunya structural proteins.
The Eilat/Chikungunya vaccine was found to be structurally identical to natural chikungunya virus. The difference is that although the hybrid virus replicates very well in mosquito cells, it cannot replicate in mammals.
Within four days of a single dose, the Eilat/Chikungunya candidate vaccine induced neutralizing antibodies that lasted for more than 290 days. The antibodies provided complete protection against chikungunya in two different mouse models. In nonhuman primates, Eilat/Chikungunya elicited rapid and robust immunity – there was neither evidence of the virus in the blood nor signs of illness such as fever after chikungunya virus infection.
Receive an email update when we add a new CHIKUNGUNYA article.
The Latest on: Chikungunya vaccine
via Google News
The Latest on: Chikungunya vaccine
- Chikungunya outbreak in Chad nears 35,000 cases since Auguston October 7, 2020 at 11:45 am
By NewsDesk @bactiman63 In a follow-up on the chikungunya outbreak in Chad, health authorities have reported 34,445 cases of Chikungunya, including one death since August 14. Cases have been ...
- FDA expands probe into safety of AstraZeneca's COVID-19 vaccineon October 1, 2020 at 4:30 am
The FDA has expanded its investigation into AstraZeneca’s COVID-19 vaccine to include data from clinical trials of prophylactics based on the same viral vector platform, Reuters reports. AstraZeneca ...
- When a mosquito bite causes persistent joint painon September 30, 2020 at 5:04 pm
Have you ever heard of a mosquito bite causing joint pain? Well, infection with the Chikungunya virus (CHIKV), which is transmitted to humans via the female Aedes aegypti and A. albopictus mosquitoes, ...
- Chad chikungunya outbreak tops 30,000 cases, Declining rate reportedon September 29, 2020 at 1:05 pm
By NewsDesk @bactiman63 In a follow-up on the chikungunya outbreak in Chad, 30,220 cases have been reported since the declaration of the outbreak in August 2020. The World Health Organization (WHO) ...
- Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Dayon September 26, 2020 at 4:36 pm
Moderna announces progress across broad portfolio and all three clinical stage therapeutic areas at 2020 R&D Day.
- Chikungunya – Chadon September 24, 2020 at 8:16 am
On 28 August 2020, the National IHR Focal Point of Chad notified WHO of an outbreak of chikungunya in Abéché, eastern Chad.
- Global Markets for Vaccine Technologies, 2020-2025: Recent Outbreaks of Covid-19 & Zika Virus Account for Recent Market Growthon September 22, 2020 at 4:25 am
and influenza vaccines. There has been increasing government interest in various parts of the world due to sudden outbreaks of major diseases such as Ebola, Zika virus, chikungunya, avian ...
- Global Markets for Vaccine Technologies, 2020-2025: Recent Outbreaks of Covid-19 & Zika Virus Account for Recent Market Growthon September 22, 2020 at 4:03 am
and influenza vaccines. There has been increasing government interest in various parts of the world due to sudden outbreaks of major diseases such as Ebola, Zika virus, chikungunya, avian influenza, ...
- Chikungunya Virus and Prospects for a Vaccineon September 15, 2020 at 5:00 pm
Chikungunya virus (CHIKV ... However, there are several vaccine candidates in preclinical and clinical development. Past vaccine development included the 181/clone25 strain, which relies on ...
via Bing News